Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06878248 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 10 | Calibr, a division of Scripps ResearchOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03765983 | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | terminated | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05368428 | Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer | terminated | N/A | 17 | Emory UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05085002 | A Study of Lerociclib in Participants With Advanced Breast Cancer | terminated | Phase 2 | 100 | EQRx, Inc.INDUSTRY | 6 | May 14, 2026 | clinicaltrials |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05452681 | Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors | terminated | N/A | 27 | University of Alabama at BirminghamOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation(PANEL) | terminated | N/A | 289 | University Hospital, RouenOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial(VEnT) | terminated | Phase 2 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04370522 | Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer(NIKOLE) | terminated | — | 32 | Spanish Breast Cancer Research GroupOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | terminated | — | 13 | University of WashingtonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women | terminated | — | 19 | Mayo ClinicOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer | terminated | N/A | 106 | Roswell Park Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01472445 | Vitamin D and Breast Cancer: Does Weight Make a Difference? | terminated | Phase 2 | 41 | Melinda TelliOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | terminated | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01521676 | Predictive Clinical and Biological Parameters in Breast Cancer(BC-BIO) | terminated | N/A | 749 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01589861 | Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer(PIKHER2) | terminated | Phase 1 / Phase 2 | 24 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01980277 | Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer(TAKTIC) | terminated | Phase 1 / Phase 2 | 68 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02525211 | Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment | terminated | Phase 3 | 59 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05488145 | A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy | terminated | N/A | 21 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02095184 | GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | terminated | N/A | 42 | University of Maryland, BaltimoreOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT00802711 | 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer | terminated | N/A | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05744375 | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab(TRANSCENDER) | terminated | Phase 2 | 2 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04791384 | Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Criterium, Inc.INDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04877912 | Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening | terminated | — | 166 | University of ChicagoOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT01780064 | Psychosocial Support to Facilitate the Return to Employment of Women With Breast Cancer(APAPI) | terminated | N/A | 128 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02570100 | Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM)(RepriM) | terminated | N/A | 56 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04202640 | Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery(PRESSODOU) | terminated | N/A | 80 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01614704 | Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility | terminated | — | 135 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05742269 | Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer(MIMIR-mTNBC) | terminated | — | 3 | Karolinska University HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | terminated | Phase 2 | 13 | Allarity TherapeuticsINDUSTRY | 7 | Mar 12, 2026 | clinicaltrials |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT06315296 | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer | terminated | N/A | 1 | Thomas Jefferson UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | terminated | Phase 1 / Phase 2 | 2 | Penn State UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | terminated | Phase 2 | 24 | Gordon Mills, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03428581 | Preventing Lymphedema in Axillary Lymph Node Dissection | terminated | N/A | 264 | Mayo ClinicOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03130439 | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | terminated | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05269160 | Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) | terminated | Phase 1 / Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04504331 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | terminated | Phase 1 | 4 | Jennifer Lee Caswell-JinOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03237572 | Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer(Breast-48) | terminated | Phase 1 | 13 | Patrick Dillon, MDOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04990895 | A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys | terminated | N/A | 8 | AHS Cancer Control AlbertaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04491864 | DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation(DWIBS) | terminated | — | 11 | Baylor Research InstituteOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer(INTEGRAL) | terminated | Phase 2 | 8 | The Methodist Hospital Research InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03289039 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | terminated | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 28, 2026source: clinicaltrials